Cargando…
Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study
OBJECTIVE: To determine the differences between recommendations by the National Comprehensive Cancer Network (NCNN) guidelines and Food and Drug Administration approvals of anticancer drugs, and the evidence cited by the NCCN to justify recommendations where differences exist. DESIGN: Retrospective...
Autores principales: | Wagner, Jeffrey, Marquart, John, Ruby, Julia, Lammers, Austin, Mailankody, Sham, Kaestner, Victoria, Prasad, Vinay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838851/ https://www.ncbi.nlm.nih.gov/pubmed/29514787 http://dx.doi.org/10.1136/bmj.k668 |
Ejemplares similares
-
Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017) -
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
por: Kurzrock, R, et al.
Publicado: (2019) -
Clinically meaningful benefit: real world use compared against the American and European guidelines
por: Dreicer, Jessica J., et al.
Publicado: (2017) -
Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies
por: Mailankody, Sham, et al.
Publicado: (2016) -
Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)